DIA dia-b tech limited

closer to human trials of diabetes compound

  1. 56,914 Posts.
    lightbulb Created with Sketch. 289
    Sydney - Thursday - August 31: (RWE Aust Business News) - Dia-B
    Tech Ltd (ASX:DIA) has moved a step closer to human clinical trials of
    its anti-diabetes compound ISF402 after the completion of trials on
    animals.
    The 28-day repeat dose study on 80 rats found that ISF402 is
    safe, said chairman Dr Michael Wooldridge.
    "The results of the repeat dose animal toxicology study has
    indicated no adverse effects at dose levels well above those planned for
    human clinical trials," he said.
    "These results show that ISF402 has a good safety profile."
    Together with the results of pharmacokinetic studies, which are
    currently underway, these studies will clear the path for Dia-B to apply
    for human ethics approval to commence Phase 1 human trials in the last
    quarter of 2006.
    The Phase 1 trial will comprise a single dose trial, with a
    likely dosing of between 2 and 30mg per kg of body weight.
    This compares to the recently completed rat trials which used
    much higher doses of 550mg/kg.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.